Medium urgency

Evaluation of Therapeutic Equivalence; Guidance for Industry; Availability

Detected August 22, 2026 · in Healthcare AI Regulation (FDA / ONC)

FDA has released final guidance on evaluating therapeutic equivalence for AI and medical devices, impacting compliance requirements for health tech and medical device companies.

Aforeworn detected this change in the Healthcare AI Regulation (FDA / ONC) space on August 22, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Health systems, medical device companies, health tech startups, and digital health compliance teams. should confirm how it applies to their specific situation before acting. There is a time constraint attached: N/A. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Healthcare AI Regulation (FDA / ONC) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

New guidance on the evaluation of therapeutic equivalence for AI and medical devices, which may affect product development and compliance strategies.

Who it affects

Health systems, medical device companies, health tech startups, and digital health compliance teams.

What you must do

Review and align product development and compliance strategies with the new FDA guidance on therapeutic equivalence.

Deadline

N/A

Source: https://www.federalregister.gov/documents/2026/08/24/2026-17215/evaluation-of-therapeutic-equivalence-guidance-for-industry-availability

Never miss a change like this again

Aforeworn watches Healthcare AI Regulation (FDA / ONC) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Healthcare AI Regulation (FDA / ONC)